依普利酮治疗高血压效果如何呢？

, Product name: Planep. Eplerenone is a new, highly selective aldosterone receptor blocker that can be used to treat heart failure, hypertension, and coronary heart disease. With the continuous progress of research, the scope of clinical application of eplerenone is constantly being expanded, and its status in the field of cardiovascular disease treatment is also constantly improving.

Subgroup analysis of the EPHESUS study also showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone in reducing systolic blood pressure (14.5 mmHg for eplerenone; 12.7 mmHg for enalapril: P=0.199) and diastolic blood pressure (11.2 mmHg for eplerenone; 11.3 mm for enalapril). Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively). Dropout due to adverse events (7.9% for eplerenone and 9.3% for enalapril at 6 months) and treatment failure rates were also equal (23.3% for eplerenone and 22.8% for enalapril at 6 months). About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups could reduce proteinuria above normal levels, but the eplerenone group was more significant (-61.5% vs -25.7%; P=0.01).

Not only that, it can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction.